Nilotinib appears beneficial in phase I study for patients with Gleevec-resistant CML

Hagop Kantarjian, Francis Giles, Susan O'Brien, Jorge Cortes, Oliver G. Ottmann, Lydia Wunderle, Barbara Wassmann, Dieter Hoelzer, Chiaki Tanaka, Paul Manley, Patricia Rae, William Mietlowski, Kathy Bochinski, Margaret Dugan, Leila Alland, Andreas Hochhaus, Kapil Bhalla, Maher Albitar, James D. Griffin

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Pages (from-to)711
Number of pages1
JournalCancer Biology and Therapy
Issue number7
StatePublished - Jul 2006
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this